MarketWatch  Oct 2  Comment 
Shares in oncology company NovoCure Ltd. fell sharply in their trading debut Friday, the latest example of investors’ waning appetite for biotechnology shares and for initial public offerings.
Benzinga  Oct 2  Comment 
Amid political grandstanding and valuation concerns, among other factors, the once high-flying healthcare sector has swiftly reversed course for the worse in recent weeks. The pain has been especially acute for biotechnology equities and...
Market Intelligence Center  Oct 2  Comment 
FierceBiotech  Oct 2  Comment 
Aduro Biotech, months removed from a $119 million IPO, is looking to settle down in Berkeley, leasing a four-story R&D complex as it presses forward with a pipeline of cancer treatments.
FierceBiotech  Oct 2  Comment 
XenoPort has changed its tune on an investigational psoriasis therapy, no longer insisting that the drug's middling efficacy and alarming safety profile merit late-stage development. Instead, the biotech is dumping the drug, cutting payroll and...
FierceBiotech  Oct 2  Comment 
Amicus Therapeutics, a biotech comeback story, is walking back plans to submit its rare disease treatment for FDA approval this year, rethinking its whole regulatory strategy after follow-up conversations with the agency.
Benzinga  Oct 2  Comment 
Shares in healthcare broadly and biotech specifically have been under pressure over the past one month. Most big biotech stocks are down since September 2. Morgan Stanley analysts have commented on the cash position and pipelines of big...
FierceBiotech  Oct 1  Comment 
A pair of erstwhile biotech IPO hopefuls made their way to the market at a significant discount, suffering the effects of a bear turn across the industry.
FierceBiotech  Oct 1  Comment 
FierceBiotech's annual Fierce 15 is out, with thousands of words from our editors on some of the most interesting up-and-coming private biotechs. Here's what some of the companies had to say in their own words.
FierceBiotech  Oct 1  Comment 
Facing an expert panel showdown at the FDA next month, Sarepta Therapeutics cobbled together a new set of positive data for its Duchenne muscular dystrophy drug eteplirsen, aiming to overcome persistent doubts about the tiny size of its key trial....


Related Articles


Biotechnology is the use of molecular biology and genetic engineering techniques to develop treatments for human diseases. Many leading companies from the industry originated in the late 70's from university research laboratories. In the 1980s after attracting venture investors and after listed in the US stock exchange,have then developed into a growing industry that uses research innovations to develop new agricultural products, biomedical tools, and human therapies such as monoclonal antibody for cancer. In 2006, 92% of employees in the biotechnology industry worked in companies that specialized in developing new drugs or medical devices and equipment, while 8% were employed in companies that specialized in agricultural products. [1] The large cap company in the group is Amgen, Genentech, Biogen-Idec, Genzyme. iShares Nasdaq Biotechnology (IBB) offers a low risk/reward investment vehicle for long term investors

Industry Information

Major Biotechnology Companies

ISTA Pharmaceuticals (ISTA)

Biotechnology Industry Trends & Forces

High Pipeline Risk for New Drugs

Dependence on Health Insurance/Medicare Coverage

Dependence on Governmental Regulations

High Volatility and Instability at Start-up

Litigation Risk

Market Share


  1. ↑ State Bioscience Initiatives 2008 Report, published by the Biotechnology Industry Organization

Top Ten/Twenty Best Selling Drugs 2009

M&A Biotechnology

Monoclonal Antibody Market 2009

Vaccine Market 2009

Global Monoclonal Antibodies Market Review 2008 (World Top Ten mAbs)

M&A Review: Pharmaceutical & Biotechnology Industry

Global Vaccine Market Review 2008 (World Top Ten Vaccines)

Ipilimumab (BMS) Review: A Cancer Breakthrough?

Denosumab (Prolia, Amgen) FDA Review & Approval

Companies in the Biotechnology Industry (193)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki